Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity

Improved Efficacy and Reduced Toxicity

Chowdhary, Mudit, MD*; Sen, Neilayan, MD*; Jeans, Elizabeth B., MD, MS*; Miller, Luke, MD*; Batus, Marta, MD; Gitelis, Steven, MD; Wang, Dian, MD, PhD*; Abrams, Ross A., MD*

American Journal of Clinical Oncology: January 2019 - Volume 42 - Issue 1 - p 1–5
doi: 10.1097/COC.0000000000000467
Original Articles: Soft Tissue

Objectives: Patients with large, high-grade extremity soft tissue sarcoma (STS) are at high risk for both local and distant recurrence. RTOG 95-14, using a regimen of neoadjuvant interdigitated chemoradiotherapy with mesna, doxorubicin, ifosfamide, and dacarbazine followed by surgery and 3 cycles of adjuvant mesna, doxorubicin, ifosfamide, and dacarbazine, demonstrated high rates of disease control at the cost of significant toxicity (83% grade 4, 5% grade 5). As such, this regimen has not been widely adopted. Herein, we report our institutional outcomes utilizing a modified interdigitated chemoradiotherapy regimen, without dacarbazine, and current radiotherapy planning and delivery techniques for high-risk STS.

Materials and Methods: Adults with large (≥5 cm; median, 12.9 cm), grade 3 extremity STS who were prospectively treated as part of our institutional standard of care from 2008 to 2016 are included. Neoadjuvant chemoradiotherapy consisted of 3 cycles of mesna, doxorubicin, and ifosfamide (MAI) and 44 Gy (22 Gy in 11 fractions between cycles of MAI) after which patients underwent surgical resection and received 3 additional cycles of MAI.

Results: Twenty-six patients received the MAI treatment protocol. At a median follow-up of 47.3 months, 23 (88.5%) patients are still alive. Three year locoregional recurrence-free survival, disease-free survival, and overall survival are 95.0%, 64.0%, and 95.0%, respectively. There have been no therapy-related deaths or secondary malignancies. The nonhematologic grade 4 toxicity rate was 7.7%.

Conclusions: Neoadjuvant interdigitated MAI radiotherapy followed by resection and 3 cycles of adjuvant MAI has resulted in acceptable and manageable toxicity and highly favorable survival in patients at greatest risk for treatment failure.

Departments of *Radiation Oncology

Medical Oncology

Orthopedic Oncology, Rush University Medical Center, Chicago, IL

M.C. and N.S. contributed equally.

Portions of this work were presented as an oral presentation at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting in Boston, MA.

The authors declare no conflicts of interest.

Reprints: Mudit Chowdhary, MD, Rush University Medical Center, Department of Radiation Oncology, 500 South Paulina, Chicago, IL 60612. E-mail: mchowdharymd@gmail.com.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.